WEKO3
アイテム
Quantitative radionuclide imaging study for enhanced drug delivery induced by near-infrared photoimmunotherapy
https://repo.qst.go.jp/records/83601
https://repo.qst.go.jp/records/83601fe704b53-7263-4e93-80d3-7fc5357a11ed
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2021-10-13 | |||||
| タイトル | ||||||
| タイトル | Quantitative radionuclide imaging study for enhanced drug delivery induced by near-infrared photoimmunotherapy | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Winnaung, Kuribayashi
× Winnaung, Kuribayashi× Atsushi, Tsuji× Aya, Sugyo× Masayuki, Fujinaga× Zhang, Ming-Rong× Tatsuya, Higashi× Winnaung, Kuribayashi× Atsushi, Tsuji× Aya, Sugyo× Masayuki, Fujinaga× Zhang, Ming-Rong× Tatsuya, Higashi |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Objective: Photoimmunotherapy (PIT) is an upcoming potential cancer treatment modality. Meanwhile, due to the limited therapeutic effect of PIT alone, the combination of anticancer agents with PIT is an option to improve the therapeutic outcome. PIT causes a super-enhanced permeability and retention (SUPR) effect. The selection of drug molecule sizes that are suitable for enhanced permeability is also important for optimizing therapeutic efficacy. Thus, a method that supports to investigate the drug delivery of varying molecular weights coupled with PIT is desirable. Here, we evaluated the SUPR effect using radiolabeled drugs of varying molecular weights ( 18F-5FU, 111In-DTPA, 99mTc-HSA-D, and 111In-IgG) to determine the appropriate drug size. Methods: PIT was conducted with an indocyanine green-labeled anti-HER2 antibody and an 808-nm laser irradiation. Mice were subcutaneously inoculated with HER2-positive cells in both legs. The tumor on one side was treated with PIT, and the contralateral side was not treated. The differences between tumor accumulations were quantitatively evaluated using positron emission tomography (PET) or single-photon emission computed tomography (SPECT). In this study, we used the four radionuclide imaging probes: 18F-5FU, a low-molecular-weight (148 Da) PET probe; 111In-DTPA, a low-molecular-weight (504 Da) SPECT probe, 99mT- HSA-D, a medium-molecular-weight (66492 Da) SPECT probe, and 111In-IgG, a high-molecular-weight (147111 Da) SPECT probe to quantify the SUPR effect induced by PIT. high-molecular-weight (147111 Da) SPECT probe to quantify the SUPR effect induced by PIT. Results: PIT-treated tumors showed significantly increased uptake of 18F-5FU (P < 0.001), 111In-DTPA (P < 0.05), and 99mTc-HSA-D (P < 0.02). A tendency toward increased accumulation of 111In-IgG was observed. These findings suggest that low- and medium-molecular-weight agents are promising candidates for combined PIT, and so are macromolecules; hence, administration after PIT could enhance their efficacy. Conclusion: The radionuclide imaging approach is elucidated for the PIT-mediated SUPR effect and can help in optimizing therapeutic measures by means of the feasibility of selecting a drug size and monitoring its distribution. Our findings encourage further preclinical and clinical studies to develop a combination therapy of PIT with conventional anticancer drugs. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | World Molecular Imaging Congress | |||||
| 発表年月日 | ||||||
| 日付 | 2021-10-07 | |||||
| 日付タイプ | Issued | |||||
